Moon Niall O, Henstridge-Blows Jemima R, Sprecher Eva A, Thomas Elizabeth, Byfield Amy, McGrane John
Royal Cornwall Hospitals NHS Trust, Truro, UK.
Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.
BMJ Oncol. 2023 Dec 18;2(1):e000160. doi: 10.1136/bmjonc-2023-000160. eCollection 2023.
The 'Godrevy Project' is an interventional trial designed to determine the effectiveness of immersive virtual reality (VR) on the holistic symptom control and well-being in oncology and palliative care patients. The primary objective of this study was to determine whether VR changed the revised Edmonton Symptom and Assessment System (ESAS-r) score representing an effective improvement in symptom control and well-being.
This study reports on 60 participants recruited from hospital inpatient oncology and palliative care lists, to participate in an unblinded, VR intervention. Participants were included aged >18 years with a diagnosis of cancer, receiving inpatient treatment of systemic anticancer therapy. Impact evaluation on symptoms was measured using the ESAS-r pre-VR and post-VR intervention. For ethical reasons, participants were not randomised.
From the 60 inpatients recruited, 58 participants were included for analysis. Participants recruited were aged 19-84 years with female (58%) and male (42%) participation. The primary outcome of the study demonstrated significant improvement in ESAS-r scores for symptoms and well-being. Total ESAS-r scores showed an improvement of 42% compared with baseline, with well-being ESAS-r scores improving 51%. The most common side effect was drowsiness. There were no adverse events related to study participation.
The 'Godrevy Project' successfully demonstrates the feasible, effective use of VR on symptom control and well-being in oncology and palliative care patients. This study demonstrates VR as an effective, patient controlled, non-pharmacological intervention without significant side effects. This interventional trial is well placed to support future research and improve clinical practice.
NCT04821466.
“戈德雷维项目”是一项干预性试验，旨在确定沉浸式虚拟现实（VR）对肿瘤学和姑息治疗患者整体症状控制及幸福感的有效性。本研究的主要目的是确定VR是否改变了经修订的埃德蒙顿症状评估系统（ESAS-r）评分，该评分代表症状控制和幸福感方面的有效改善。
本研究报告了从医院肿瘤内科和姑息治疗住院患者名单中招募的60名参与者，他们参与了一项非盲法VR干预。纳入的参与者年龄>18岁，诊断为癌症，正在接受全身抗癌治疗的住院治疗。使用VR干预前和干预后的ESAS-r对症状进行影响评估。出于伦理原因，参与者未进行随机分组。
在招募的60名住院患者中，58名参与者纳入分析。招募的参与者年龄在19至84岁之间，女性（58%）和男性（42%）均有参与。研究的主要结果表明，ESAS-r症状和幸福感评分有显著改善。与基线相比，ESAS-r总分提高了42%，幸福感ESAS-r评分提高了51%。最常见的副作用是嗜睡。没有与参与研究相关的不良事件。
“戈德雷维项目”成功证明了VR在肿瘤学和姑息治疗患者的症状控制及幸福感方面的可行且有效应用。本研究表明VR是一种有效的、患者可控的、无显著副作用的非药物干预措施。这项干预性试验为支持未来研究和改善临床实践奠定了良好基础。
NCT04821466。
